{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:51Z","timestamp":1787162451736,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hyperlipidemia, the most common form of dyslipidemia, is associated with an increased risk of atherosclerotic cardiovascular diseases. There is a constant demand for therapeutic agents with relatively few side effects that can be administered from the initial stage of hyperlipidemia, herbal medicines derived from natural products can be considered candidates for treating dyslipidemia. This study aims to explore the feasibility, preliminary effectiveness, and safety of Gyejibongnyeong-Hwan (GBH) in patients with hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a 2-armed, parallel, multicenter, and exploratory randomized controlled trial on dyslipidemia. We will recruit 90 patients aged 20 to 65 years with hyperlipidemia between November 2021 and December 2022. Eligible participants will be randomly assigned to receive GBH or placebo granules for 8 weeks and followed up for 4 weeks after 4 weeks of lifestyle modification. The primary outcome is the percentage changes in low-density lipoprotein cholesterol from baseline to week 8. The secondary outcomes are percentage changes in other blood lipid parameters, blood glucose parameters, and blood stasis scores. As an exploratory outcome measure, metabolite analysis will be conducted to observe changes in metabolic patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This is the first randomized controlled trial to explore the clinical effect and safety of GBH compared to placebo control in patients with hyperlipidemia, thereby potentially facilitating better management of hyperlipidemia. The results of this pilot study could form a foundation for future large-scale confirmatory clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination:<\/jats:title>\n                    <jats:p>This study was permitted by the Ministry of Food and Drug Safety on investigational new drug application on August 12, 2021 and approved by the Institutional Review Board of Kyung Hee University, Seoul, Republic of Korea (KOMCIRB202110012001) on November 26, 2021. The results will be published in a peer-reviewed journal and disseminated electronically and in print.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000033093","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T11:37:34Z","timestamp":1682077054000},"page":"e33093","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The clinical effects of Gyejibongnyeong-Hwan (Gui Zhi Fu Ling Wan) on patients with hyperlipidemia: A study protocol for a multicenter, double-blind, two-armed parallel, investigator-initiated, exploratory randomized controlled trial"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-4655","authenticated-orcid":false,"given":"Mi Mi","family":"Ko","sequence":"first","affiliation":[{"name":"KM Science Research Division, Korea Institute of Oriental Medicine, Yuseong-daero 1672, Yuseong-gu, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyung-Wha","family":"Kim","sequence":"additional","affiliation":[{"name":"Clinical Research Coordinating Team, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Jung","sequence":"additional","affiliation":[{"name":"Clinical Research Coordinating Team, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Neuroscience, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Cheol","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyoun","family":"Jung","sequence":"additional","affiliation":[{"name":"KM Science Research Division, Korea Institute of Oriental Medicine, Yuseong-daero 1672, Yuseong-gu, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia.","volume":"23","author":"Karr","year":"2017","journal-title":"Am J Manag Care"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.12997\/jla.2021.10.2.202","article-title":"Dyslipidemia fact sheets in Korea 2020: an analysis of nationwide population-based data.","volume":"10","author":"Cho","year":"2021","journal-title":"J Lipid Atheroscler"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1515\/CCLM.2005.085","article-title":"Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified ApoE and LDLR mice.","volume":"43","author":"Wouters","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects.","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250504","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects.","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"R9-20250504","first-page":"1","article-title":"Drug research and development tend to hyperlipidemia.","volume":"18","author":"Seol","year":"2009","journal-title":"J Daejeon Univ Oriental Med Res Inst"},{"key":"R11-20250504","first-page":"66","article-title":"\u9ad8\u8102\u8840\u75c7\u6cbb\u6cd5\u5be9\u6790.","volume":"29","author":"\u8d99","year":"1988","journal-title":"\u4e2d\u91ab\u96dc\u8a8c"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"163036","DOI":"10.1155\/2014\/163036","article-title":"Chinese herbal medicine on dyslipidemia: progress and perspective.","volume":"2014","author":"Guo","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"R13-20250504","first-page":"9","article-title":"Review of Korean medical treatment in hyperlipidemia-focusing on treatment of Korean herbal medicine.","volume":"24","author":"Hong","year":"2010","journal-title":"J Physiol Pathol Kor Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15204\/jkobgy.2016.29.2.099","article-title":"The analysis of the experimental research trend of efficacy of Gyejibokryeong-hwan.","volume":"29","author":"Jang","year":"2016","journal-title":"J Korean Obstet Gynecol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2007.11.019","article-title":"Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.","volume":"80","author":"Nakagawa","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"801291","DOI":"10.1155\/2015\/801291","article-title":"Effect of keishibukuryogan on genetic and dietary obesity models.","volume":"2015","author":"Gao","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"R18-20250504","first-page":"21","article-title":"\u6842\u679d\u832f\u82d3\u4e38\u8f85\u52a9\u6cbb\u7597\u9ad8\u8102\u8840\u75c760\u4f8b\u7597\u6548\u89c2\u5bdf.","volume":"43","author":"\u5b59","year":"2011","journal-title":"New Chin Med"},{"key":"R19-20250504","first-page":"444","article-title":"\u6842\u679d\u832f\u82d3\u4e38\u6cbb\u7597\u9ad8\u8102\u8840\u75c739\u4f8b.","volume":"16","author":"\u799a","year":"1997","journal-title":"\u5c71\u4e1c\u4e2d\u533b\u6742\u5fd7"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.2009.05265.x","article-title":"The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease.","volume":"1190","author":"Fujimoto","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R21-20250504","first-page":"24","article-title":"Improving vascular endothelial function by \u201cGyejibongnyeong-hwan (Guizhi Fuling Wan)\u201d in patients with hypercholesterolemia.","volume":"46","author":"Yokokawa","year":"2014","journal-title":"Phil Kampo"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/M16-2977","article-title":"CONSORT Extension for Chinese Herbal Medicine Formulas 2017: recommendations, explanation, and elaboration.","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann Intern Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"R25-20250504","first-page":"287","article-title":"Sample size of 12 per group rule of thumb for a pilot study.","volume":"4","author":"Julious","year":"2005","journal-title":"Pharm Stat J Appl Stat Pharm Ind Pharmaceut Statist"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","article-title":"Assessment of blinding in clinical trials.","volume":"25","author":"Bang","year":"2004","journal-title":"Control Clin Trials"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ecam\/nel025","article-title":"Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis.","volume":"3","author":"Nozaki","year":"2006","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:22:57Z","timestamp":1746307377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033093","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}